01—Abstract
Summary
Summary of the 8-K filed July 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) filed this Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce additional results from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis.
The new data will be presented on July 4, 2024 at the 7th World Bronchiectasis Conference in Dundee, Scotland, by lead investigator James Chalmers. The filing states that the study previously met its primary endpoint: annualized pulmonary exacerbation rates were 1.015 for the 10 mg group, 1.036 for the 25 mg group, and 1.286 for placebo, a 21.1%a risk reduction for 10 mg (p=0.0019) and a 19.4% risk reduction for 25 mg (p=0.0046). The new findings center on lung function and exploratory endpoints.
For the 25 mg dose, FEV1 decline at Week 52 was significantly less than placebo, with an LS mean difference of 38 mL (p=0.0054), while placebo patients lost an average of 62 mL. Nominally significant FVC improvement of 75 mL versus placebo (p<0.0001) and a nominally significant 3.8-point improvement in the QOL-B Respiratory Symptom Domain score (p=0.0004) were also reported for the 25 mg dose. Brensocatib was described as well tolerated, with a safety profile comparable to placebo.
The company plans to file a New Drug Application with the FDA in the fourth quarter of 2024 and anticipates a U.S. launch in mid-2025, with launches in Europe and Japan in the first half of 2026, pending regulatory approvals. Brensocatib is investigational and has not been approved in any jurisdiction.
For investors, the filing is primarily a data-communication update that reinforces the company's regulatory timeline. The 8-K itself contains no financial statements, and the press release and slide deck are furnished rather than filed under Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Additional ASPEN Phase 3 data on brensocatib to be presented July 4, 2024 at the 7th World Bronchiectasis Conference in Dundee, Scotland.
- 25 mg dose showed significantly less FEV1 decline versus placebo at Week 52 (LS mean difference of 38 mL, p=0.0054); placebo lost 62 mL on average.
- Nominally significant FVC improvement for the 25 mg dose versus placebo (LS mean difference of 75 mL, p<0.0001), an exploratory endpoint.
- Nominally significant 3.8-point improvement in QOL-B Respiratory Symptom Domain score for the 25 mg dose versus placebo (p=0.0004).
- Primary endpoint previously met: 21.1% risk reduction in pulmonary exacerbations for 10 mg (p=0.0019) and 19.4% for 25 mg (p=0.0046).
- Favorable safety profile reported, with treatment-emergent adverse event rates comparable to placebo.
- NDA submission planned for Q4 2024; anticipated U.S. launch in mid-2025 and Europe and Japan launches in the first half of 2026, pending approvals.
03—Questions
Frequently Asked Questions
What is new in this disclosure compared with the previously announced ASPEN topline results?
The filing announces additional data to be presented at the World Bronchiectasis Conference, including the 52-week FEV1 and FVC lung function results, the QOL-B Respiratory Symptom Domain score, and the exploratory BEST score. The primary exacerbation endpoint was previously announced and is restated in the filing.
How significant are the lung function results?
For the 25 mg dose, the FEV1 decline versus placebo was statistically significant (p=0.0054), and the FVC result was reported with p<0.0001. The filing describes the FVC and QOL-B findings as nominally significant, and the FVC and BEST endpoints are exploratory.
What did the 10 mg dose show on the lung function endpoint?
The filing reports that the 10 mg dose showed an LS mean change of -50 mL in post-bronchodilator FEV1 at Week 52, versus -62 mL for placebo, a difference of 11 mL with p=0.3841, which is not statistically significant.
What is the regulatory and commercial timeline?
Insmed plans to file a New Drug Application with the FDA in the fourth quarter of 2024. Pending approvals, it anticipates a U.S. launch in mid-2025 and launches in Europe and Japan in the first half of 2026. Brensocatib is investigational and has not been approved for any indication.
What were the key safety findings?
Brensocatib was described as well tolerated. Among the most common adverse events, COVID-19 occurred in 15.8% (10 mg), 20.9% (25 mg), and 15.8% (placebo) of patients. Adverse events leading to death were 0.5% (10 mg), 0.7% (25 mg), and 1.2% (placebo).
04—Continue